RIPK2 Dictates Insulin Responses to Tyrosine Kinase Inhibitors in Obese Male Mice
Clicks: 205
ID: 110985
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
205 views
23 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #53 of 213 articles by views in endocrinology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 213 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract. Tyrosine kinase inhibitors (TKIs) used in cancer are also being investigated in diabetes. TKIs can improve blood glucose control in diabetic cancer p
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (24 words).
Try re-searching for a better abstract.
| Reference Key |
m2020endocrinologyripk2
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Duggan, Brittany M;Cavallari, Joseph F;Foley, Kevin P;Barra, Nicole G;Schertzer, Jonathan D; |
| Journal | endocrinology |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.